Genomic and Immune Determinants of Resistance to Anti-CD38 MoAb Based Therapy in Relapsed Multiple Myeloma

被引：0
|
作者：
Ziccheddu, Bachisio [1 ]
Giannotta, Claudia [2 ]
D'Agostino, Mattia [3 ]
Bertuglia, Giuseppe [3 ]
Saraci, Elona [4 ]
Oliva, Stefania [3 ]
Diamond, Benjamin [1 ]
Bolli, Niccolo [5 ]
Corradini, Paolo [6 ,7 ]
Coffey, David [8 ]
Landgren, Ola [1 ]
Bruno, Benedetto [3 ]
Boccadoro, Mario [3 ]
Massaia, Massimo [9 ]
Maura, Francesco [1 ]
Larocca, Alessandra [3 ]
机构：
[1] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr Guido Tarone, Lab Blood Tumor Immunol, Turin, Italy
[3] Univ Torino, Div Hematol, Myeloma Unit, Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy
[4] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[5] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Ematol, Milan, Italy
[6] Univ Milan, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Pinecrest, FL USA
[9] Santa Croce & Carle Hosp, Div Hematol, Cuneo, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
    Mohyuddin, Ghulam Rehman
    Chakraborty, Rajshekhar
    Calip, Gregory
    Ascha, Mustafa S.
    Wang, Xiaoliang
    Rubinstein, Samuel
    Tuchman, Sascha A.
    Costa, Luciano J.
    Haaland, Benjamin
    Giri, Smith
    Mian, Hira S.
    Fonseca, Rafael
    Sborov, Douglas W.
    BLOOD, 2022, 140 : 5223 - 5224
  • [22] Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
    De Novellis, Danilo
    Fontana, Raffaele
    Giudice, Valentina
    Serio, Bianca
    Selleri, Carmine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [23] Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
    Ghulam Rehman Mohyuddin
    Rajshekhar Chakraborty
    Gregory S. Calip
    Mustafa S. Ascha
    Xiaoliang Wang
    Samuel M. Rubinstein
    Sascha Tuchman
    Luciano Costa
    Benjamin Haaland
    Smith Giri
    Hira Mian
    Rafael Fonseca
    Douglas Sborov
    Blood Cancer Journal, 12
  • [24] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Oses, Lucrecia
    Brulc, Erika
    Carretero, Marcelina
    Nucifora, Elsa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [25] A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
    Zhang, Huan
    Liu, Man
    Xiao, Xia
    Lv, Hairong
    Jiang, Yanyu
    Li, Xin
    Yuan, Ting
    Zhao, Mingfeng
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1418 - 1427
  • [26] Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?
    D'Agostino, Mattia
    Mina, Roberto
    Gay, Francesca
    LANCET HAEMATOLOGY, 2020, 7 (05): : E355 - E357
  • [27] The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
    Moreno, Laura
    Perez, Cristina
    Zabaleta, Aintzane
    Manrique, Irene
    Alignani, Diego
    Ajona, Daniel
    Blanco, Laura
    Lasa, Marta
    Maiso, Patricia
    Rodriguez, Idoia
    Garate, Sonia
    Jelinek, Tomas
    Segura, Victor
    Moreno, Cristina
    Merino, Juana
    Rodriguez-Otero, Paula
    Panizo, Carlos
    Prosper, Felipe
    San-Miguel, Jesus F.
    Paiva, Bruno
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 3176 - 3187
  • [28] Serological Investigation in a Multiple Myeloma Patient receiving Daratumumab (Anti-CD38)
    Oldfield, L.
    Ison, T.
    Lau, W.
    TRANSFUSION, 2016, 56 : 135A - 136A
  • [29] Efficacy and safety of anti-CD38 antibodies in combination with pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
    Sato, Tsuyoshi
    Asano, Kazuya
    Maeta, Takahiro
    Kiyohara, Kazuki
    Miyajima, Shinri
    Otsu, Akihiro
    Nishiya, Maki
    Sasaki, Ryousei
    Okano, Yoshiaki
    Kamihara, Satsuki
    Kowata, Shugo
    Oyake, Tatsuo
    Ito, Shigeki
    ANNALS OF ONCOLOGY, 2023, 34 : S1446 - S1446
  • [30] Safety and Tolerability of Anti-CD38 Monoclonal Antibodies (mAb) in Multiple Myeloma
    Thet, Aye
    Myint, Phyo Thazin
    Hadid, Tarik
    BLOOD, 2022, 140 : 12552 - 12553
12345